Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This is a phase I study of perifosine in combination with lenalidomide and dexamethasone for
patients with relapsed or refractory multiple myeloma. The current protocol will enroll
patients with relapsed or refractory multiple myeloma requiring second or third line therapy.
Six patients each will be treated with at one of 4 dose levels in a phase 1 study. All
patients will receive perifosine, lenalidomide and dexamethasone of each 28 day cycle. The
doses of perifosine and lenalidomide will be varied in each group. The dose of dexamethasone
will remain constant.